Reviva Pharmaceuticals Holdings, Inc. held its Annual Meeting on December 18, 2025, where stockholders approved increasing authorized shares from 315 million to 515 million and a potential reverse stock split ranging from 1-for-2 to 1-for-20. The sentiment is neutral, and the event is significant for the company.